Sensus Healthcare Inc. has announced that its entire portfolio of superficial radiation therapy $(SRT)$ systems, including the SRT-100®, SRT-100+™, and SRT-100 Vision™, has received certification under the Medical Device Single Audit Program (MDSAP). This certification is expected to streamline the company's international regulatory efforts and accelerate its commercial expansion into key global markets. The MDSAP certification enhances Sensus Healthcare's ability to engage with international hospital systems and specialty clinics, offering a compelling advantage in markets where regulatory pathways can be challenging. Additionally, the company anticipates that its TransDermal Infusion $(TDI)$ product will also receive MDSAP certification following FDA clearance, further boosting its commercial potential outside the U.S.